PPARGC1A and atrial fibrillation: The pharmacological activation of AMPK and its downstream regulator, PGC-1α, can retard/reverse the pathological processes underlying AF in human [143,144] and pre-clinical AF models induced by rapid atrial pacing [145,146,147] and obesity [81], in addition to genetic modified rodents [148].